Panacea Biotech launches ViLACT for diabetes patients

Panacea Biotech Limited has announced launch of brand ViLACT in India. ViLACT is used in the treatment of Uncontrolled Type 2 Diabetes Mellitus patients with HbA1c >6.5 per cent.

As per AIOCD MAT October 2019 data, the total market size of this molecule and its combination is Rs. 969 crores and is growing at the rate of 4 per cent.

Vildagliptin is a new oral antidiabetic agent that enhances pancreatic islet cell responsiveness to glucose, is an incretin enhancer, a potent and selective inhibitor of dipeptidyl peptidase-4 (DPP-4), the enzyme responsible for the rapid degradation of the incretin hormones glucagon-like peptide-1 (GLP-l) and glucose-dependent insulinotropic peptide (GIP).

This activity increases levels of active incretins and enhances pancreatic islet responsiveness to glucose, thus, improving insulin secretion and reducing inappropriate glucagon production, improving insulin sensitivity, improving postprandial lipid and lipoprotein metabolism, and reducing fasting and prandial glucose and HbA1c.

Diacar Strategic Business Unit (SBU) has launched ViLACT brand family. This will open up a new segment for accelerated growth of the SBU. The ViLACT brand will be an affordable, high quality medicine in the armamentarium of a physician treating patients with Diabetes.

On Tuesday, stock of Panacea Bio opened at Rs. 117 on BSE. During the morning trading session, it touched Rs. 122.30, up by 5.6 per cent.